期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识（2016版） 被引量：62

原文传递
导出
摘要 一、表皮生长因子受体（epidermalgrowthfactorreceptor，EGFR）基因突变检测的临床意义EGFR是一种跨膜受体酪氨酸激酶，该区域的激活即磷酸化对癌细胞增殖、生长的相关信号传递具有重要意义。因此，EGFR作为癌症治疗的分子靶标受到普遍关注，并陆续开发出了吉非替尼（gefitinib）、厄洛替尼（erlotinib）和埃克替尼（icotinib）等EGFR酪氨酸激酶抑制剂（tyrosinekinaseinhibitor，TKI）和抗EGFR抗体等。
作者 梁智勇 周晓燕
机构地区 北京协和医院病理科 复旦大学附属肿瘤医院病理科
出处 《中华病理学杂志》 CAS CSCD 北大核心 2016年第4期217-220,共4页 Chinese Journal of Pathology
关键词 表皮生长因子受体基因 突变检测 EGFR酪氨酸激酶抑制剂 肺癌患者 非小细胞 受体酪氨酸激酶 专家 中国
分类号 R73 [医药卫生—肿瘤]
  • 相关文献

参考文献30

  • 1Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer[J]. Cancer Sci, 2007, 98 (12) : 1817-1824. DOI: 10. 1111/j. 1349-7006. 2007. 00607. x.
  • 2Douillard JY, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study [ J ]. Br J Cancer, 2014, 110 ( 1 ): 55-62. DOI: 10. 1038/bjc. 2013. 721.
  • 3Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations[J]. Clin Cancer Res, 2012, 18(4): 1167-1176. DOI: 10. 1158/1078-0432. CCR-11-2109.
  • 4Tatematsu A, Shimizu J, Murakami Y, et al. Epidermal growth factor receptor mutations in small cell lung cancer [ J ]. Clin Cancer Res, 2008, 14 ( 19 ) :6092-6096. DOI: 10. 1158/1078- 0432. CCR-08-0332.
  • 5Mok T, Wu YL, Thongprassert S, et al. Phase 111, randomized, open-label, first-line study of gefitinib vs catboplatin/paclitaxel inclinically selected patients with advanced non. small cell lung cancer(ESMO 2008, LBA2 ) [ J ]. Ann Oncol, 2008, 19 ( suppl 8) : V/II.
  • 6Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor ( WJTOG3405 ) : an open label, randomised phase 3 trial [ J ]. Laneet Oncol, 2010, 11 (2) : 121-128. DOI: 10. 1016/$1470- 2045 ( 09 ) 70364-X.
  • 7Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-eell lung cancer with mutated EGFR[J]. N Engl J Med, 2010, 362(25):2380-2388. DOI: 10. 1056/NEJMoa0909530.
  • 8Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenoearcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan[ J]. J Clin Oncol, 2008, 26 (34) :5589-5595. DOI:10. 1200/JCO. 2008.16. 7254.
  • 9NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines~) Non-Small Cell Lung Cancer Version 2. 2014. [ EB/OL].
  • 10Douillard JY, Hirsh V, Mok T, et al. Molecular and clinical subgroup analyses from a phase llI trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST) [J].J Clin Oncol, 2008, 26 (suppl) : Abstr 8001.

二级参考文献53

  • 1Park S,Holmes-Tisch AJ,Cho EY. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small celt lung cancer.J Thorac Oncol,2009,4 (7):809-815.
  • 2Gow CH,Chang YL,Hsu YC,et al.Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-na(i)ve non-small-cell lung cancer.Ann Oncol,2009,20(4):696-702.
  • 3Jorissen RN,Walker F,Pouliot N,et al.Epidermal growth factor receptor:mechanisms of activation and signaling.Exp Cell Res,2003,284(1):31-53.
  • 4Shigematsu H,Lin L,Takahashi T,et al.Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.J Natl Cancer Inst,2005,97(5):339-346.
  • 5Tamura K,Okamoto I,Kashii T,et al.Multicentre prospective phase Ⅱ trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations:results of the West Japan Thoracic Oncology Group trial(WJTOG0403).Br J Cancer,2008,98(5):907-914.
  • 6Chan SK,Gullick WJ,Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer search and destroy.Eur J Cancer,2006,42 (1):17-23.
  • 7Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in The epidermal growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib.N Engl J Med,2004,350(21):2129-2139.
  • 8Paez JG,Janne PA,Lee JC,et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.Science,2004,304(5676):1497-1500.
  • 9Sasaki H,Endo K,Konishi A,et al.EGFR mutation status in Japanese lung cancer patients:genotyping analysis using Light Cycler.Clin Cancer Res,2005,11 (8):2924-2929.
  • 10Paez JG,Janne PA,Lee JC,et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.Science,2004,304 (5676):1479-1500.

共引文献89

同被引文献451

引证文献62

二级引证文献400

中华病理学杂志
2016年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部